Drew Voytal
Drew Voytal, MPA is a Senior Director of public affairs at PhRMA focusing on advocacy and policy communications on key issues, including 340B. His career in health care advocacy, policy and public affairs spans more than a decade in Washington, DC where he has built relationships with key government and industry partners to advance public policy priorities. Drew has personally experienced the benefits of biopharmaceutical research and innovation and is passionate about telling the story of this vital industry.
From lab to medicine cabinet: Following a medicine’s path to patients
Staffing up: Building the future biopharma workforce to keep America in the lead
World Sickle Cell Day: Recognizing the promise of gene therapy
America's cancer research progress is real and worth protecting
New report shows promising pipeline for cell and gene therapies, but access challenges persist
Celebrating STEM Day: Investing in America’s innovators
Manufacturing U.S. jobs and breakthroughs
Bringing to life the full story of biopharmaceutical innovation and investments
NYT exposes hospitals, middlemen make millions off a hospital markup program
New 340B report from Minnesota exposes steep hospital markups on medicines, patient benefits remain unclear
Celebrating advances in diabetes research
340B spending is exploding, forcing prices up for patients, employers and government programs
PhRMA urges HRSA not to impede new 340B pricing approaches to improve transparency and integrity
Drew Voytal